Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Efficacy and safety of COX 2 inhibitors.

× No keyword cloud information.

8 in total

1. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

Authors: Peter Jüni; Anne W S Rutjes; Paul A Dieppe
Journal: BMJ Date: 2002-06-01

2. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors: F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal: JAMA Date: 2000-09-13 Impact factor: 56.272

Review 3. NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action.

Authors: Syeda S Husain; Imre L Szabo; Andrzej S Tamawski
Journal: Am J Gastroenterol Date: 2002-03 Impact factor: 10.864

4. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors: C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal: N Engl J Med Date: 2000-11-23 Impact factor: 91.245

Review 5. Review article: COX-2, prostanoids and colon cancer.

Authors: S Ota; H Bamba; A Kato; C Kawamoto; Y Yoshida; K Fujiwara
Journal: Aliment Pharmacol Ther Date: 2002-04 Impact factor: 8.171

6. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis.

Authors: Douglas J Watson; Thomas Rhodes; Bing Cai; Harry A Guess
Journal: Arch Intern Med Date: 2002-05-27

Review 7. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.

Authors: Jonathan J Deeks; Lesley A Smith; Matthew D Bradley
Journal: BMJ Date: 2002-09-21

8. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.

Authors: Muhammad Mamdani; Paula A Rochon; David N Juurlink; Alex Kopp; Geoffrey M Anderson; Gary Naglie; Peter C Austin; Andreas Laupacis
Journal: BMJ Date: 2002-09-21

8 in total

1. Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity.

Authors: Peter Juni; Rebekka Sterchi; Paul Dieppe
Journal: BMJ Date: 2003-02-08

2. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.

Authors: Julia Hippisley-Cox; Carol Coupland
Journal: BMJ Date: 2005-06-11

3. Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: COX-2 inhibitors were thought of as a safe option.

Authors: Michael R Lewis; Diana Kay
Journal: BMJ Date: 2005-12-17

4. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.

Authors: Julia Hippisley-Cox; Carol Coupland; Richard Logan
Journal: BMJ Date: 2005-12-03

8. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.

Authors: Yola Moride; Thierry Ducruet; Jean-François Boivin; Nicholas Moore; Sylvie Perreault; Sean Zhao
Journal: Arthritis Res Ther Date: 2005-01-17 Impact factor: 5.156

8 in total

Efficacy and safety of COX 2 inhibitors.

1. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

2. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Review 3. NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action.

4. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Review 5. Review article: COX-2, prostanoids and colon cancer.

6. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis.

Review 7. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.

8. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.

1. Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity.

2. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.

3. Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: COX-2 inhibitors were thought of as a safe option.

4. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.

5. Cardiovascular and gastrointestinal safety of selective cyclooxygenase-2 inhibitors: a case/non-case study.

Review 6. COX-2 inhibitors and the heart: are all coxibs the same?

7. Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits.

8. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.